Targeting hexokinase 2 in castration-resistant prostate cancer
Authors:
Open Access
- 23 January 2015
- journal article
- editorial
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 2 (3) , e974465
Abstract
Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.Keywords
This publication has 9 references indexed in Scilit:
- Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer GrowthCell Reports, 2014
- Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of CancerCancer Cell, 2013
- A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerNature Genetics, 2013
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiformeJournal of Experimental Medicine, 2011
- The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA levelAnnals of Nuclear Medicine, 2010
- Molecular genetics of prostate cancer: new prospects for old challengesGenes & Development, 2010
- Enzymatic properties of the N- and C-terminal halves of human hexokinase II.BMB Reports, 2009
- 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment ResponseJournal of Nuclear Medicine, 2009
- Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic functionJournal of Experimental Biology, 2003